PSG Validation of MATRx Plus AHI
|ClinicalTrials.gov Identifier: NCT03627169|
Recruitment Status : Active, not recruiting
First Posted : August 13, 2018
Last Update Posted : April 18, 2019
Obstructive sleep apnea (OSA) is a common disease that carries significant risks for cardiovascular disease, mortality, and economic costs. Almost thirty years ago, initial population studies found the prevalence of OSA to be five to nine percent of the adult population. Excess body weight is a risk factor for the development of OSA, and the recent rise in prevalence of obesity has led to revised estimates of OSA prevalence, now at seventeen per cent of the adult population. OSA is poorly recognized clinically; 85% of apneics remain undiagnosed and untreated.
Currently, the diagnosis of OSA commonly relies on an overnight, in-hospital polysomnogram (PSG). Due to the extensive attachments to the body surface required in a PSG, it has developed a negative impression. Any effective solution to the public health challenges posed by sleep apnea will have to consider the need for less cumbersome and off-putting methods.
Zephyr Sleep Technologies has developed a device that has been approved for use in Canada. The MATRx plus device functions as both a Level III sleep recorder (records respiratory airflow, respiratory effort, pulse rate, and arterial oxygen saturation) as well as a home-based system to select patients for oral appliance therapy. The American Academy of Sleep Medicine (AASM) recommends the use of apnea-hypopnea index (AHI) for the diagnosis and categorization of OSA severity. The Level III function of the MATRx plus device is approved for use in Canada with two autoscoring methods: oxygen desaturation index, ODI and apnea-hypopnea index, AHI, but requires further validation of AHI for clearance by the US Food and Drug Administration (FDA).
The proposed research will validate the AHI autoscoring function of the MATRs plus Level III home sleep recorder by comparing it to data recorded in a PSG, which is considered to be the gold standard for sleep testing. Though the effectiveness of the AHI autoscoring algorithm has been previously established, it has not been validated against PSG data. Additionally, other parameters such as snoring will be examined in order to develop scoring algorithms for other facets of sleep disordered breathing.
|Condition or disease||Intervention/treatment|
|Obstructive Sleep Apnea||Device: MATRx plus|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||PSG Validation of MATRx Plus AHI|
|Actual Study Start Date :||July 25, 2017|
|Estimated Primary Completion Date :||July 25, 2019|
|Estimated Study Completion Date :||August 31, 2019|
MATRx plus/PSG group
Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
Device: MATRx plus
The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
- Apnea and hypopnea events [ Time Frame: 1 night ]The number of apnea and hypopnea events collected from each the MATRx plus device and PSG will be recorded in order to determine the sensitivity/specificity of the MATRx plus device.
- Snoring events [ Time Frame: 1 night ]The number of snoring events
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03627169
|Zephyr Sleep Technologies|
|Calgary, Alberta, Canada, T2H2C3|